Results 11 to 20 of about 219,955 (289)
New England Journal of Medicine, 2011 Clinical presentations 310Investigation 311Clinical course 311Management 31225% of inflammatory bowel disease presents in childhood, 1/3 as ulcerative colitis.
R. Mark Beattie +2 more
core +4 more sources
The Lancet, 2012 Ulcerative colitis is an idiopathic, chronic inflammatory disorder of the colonic mucosa, which starts in the rectum and generally extends proximally in a continuous manner through part of, or the entire, colon; however, some patients with proctitis or left-sided colitis might have a caecal patch of inflammation.
Ordás, Ingrid +4 more
+9 more sources
Psychological stress and hypnosis in ulcerative colitis. [PDF]
, 2008 PhDPrevious studies suggest that life events and chronic stress increase the risk of relapse in inflammatory bowel disease. Furthermore, experimental stress has been shown to worsen inflammation in animal models of colitis.
Mawdsley, Joel Evan David
core +4 more sources
Recenti progressi in medicina, 2016 Inflammatory bowel disease (IBD), such as Crohn's disease (CD) and ulcerative colitis (UC), are chronic, relapsing inflammatory disorders of the digestive tract resulting from dysregulated immune responses toward environmental factors in genetically predisposed individuals.
Lopetuso, Loris Riccardo +1 more
openaire +4 more sources
Mayo Clinic Proceedings, 2019 Ulcerative colitis (UC) is a chronic inflammatory bowel disease that can involve any aspect of the colon starting with mucosal inflammation in the rectum and extending proximally in a continuous fashion. Typical symptoms on presentation are bloody diarrhea, abdominal pain, fecal urgency, and tenesmus.
Joseph D. Feuerstein +2 more
openaire +2 more sources
The Lancet, 2017 Ulcerative colitis is a chronic inflammatory disease affecting the colon, and its incidence is rising worldwide. The pathogenesis is multifactorial, involving genetic predisposition, epithelial barrier defects, dysregulated immune responses, and environmental factors.
Ungaro, Ryan +4 more
openaire +2 more sources
Use of new, once-daily 5-aminosalicylic acid preparations in the treatment of ulcerative colitis. Is there anything new under the sun? [PDF]
, 2009 5-aminosalicylate (5-ASA) agents remain the mainstay treatment in ulcerative colitis (UC). A number of oral 5-ASA agents are commercially available, including azobond pro-drugs, as well as delayed- and controlled-release forms of mesalazine.
Lakatos, Péter László
core +1 more source
Delayed Resolution of Acute Inflammation in Ulcerative Colitis Is Associated with Elevated Cytokine Release Downstream of TLR4 [PDF]
, 2010 Background: Ulcerative colitis (UC) is widely viewed as a leukocyte-mediated disorder. Although strong evidence implicates an exuberant response to microbial components in its pathogenesis, no intrinsic immune defect has been identified and the ...
Bu'Hussain Hayee +17 more
core +2 more sources
PLoS ONE, 2021 The burden of inflammatory bowel disease (IBD) in Australia is increasing but national data about the current prevalence are limited. We aimed to estimate the prevalence of IBD (including Crohn's disease, ulcerative colitis and unspecified IBD) as well ...
Doreen Busingye +2 more
doaj +1 more source
Smoking in inflammatory bowel diseases: Good, bad or ugly? [PDF]
, 2007 Smoking is an important environmental factor in inflammatory bowel disease (IBD), having different effects in ulcerative colitis (UC) and Crohn’s disease (CD).
Peter Laszlo Lakatos +5 more
core +1 more source